… MEK inhibitor (CI-1040) was carried out by LoRusso and colleagues, 34 numerous clinical
studies have been conducted to evaluate various MEK inhibitors… As KRAS mutations predict a …

… of KRAS mutation subtype vs efficacy, are ongoing. Conclusions: MEK inhibition with trametinib
+ pem demonstrates tolerability and clinical activity in both KRAS-mutant and WT NSCLC…

… Aberrant hyperactivation of KRAS plays a prominent role in … KRAS mutations comprise
>80% of all RAS mutations and are … of MEK inhibitors to inhibit ERK signaling in KRAS-mutant …

… that upon maximal MEK inhibition, KRAS M cell lines showed significantly greater GI compared
with KRAS WT cell lines. However, the GI caused by MEK inhibition in KRAS M cell lines …

… combination targets for trametinib, a MEK inhibitor approved by the US Food and Drug
Administration, which acts downstream of KRAS to suppress signalling through the mitogen-…

… with MEK inhibitors in KRAS mutant cell lines (Figure 2A). This suggests that paradoxical
activation is not the primary reason type 1.5 RAF inhibitors do not synergize with MEK inhibitors …

… To determine whether inhibition to downstream signaling of Kras specifically sensitized
KRAS mutant lung cancer cells, we focused on the MEK1/2 inhibitors, given the importance of …

… a panel of 16 KRAS mutant colorectal, lung, and pancreatic cancer cell lines to PD0325901,
a potent and selective MEK inhibitor, to ascertain their dependence on MEK signaling for …

… Out data indicated that for NSCLC patients with EGFR or KRAS mutations, inhibition of the
PI3K pathway alone or in combination with the MEK inhibitor may suppress tumor growth, and …

… Background: Preclinical experiments in-vitro show MEK inhibitors can cause upregulation
of p-FAK in KRAS M cells. The combination of a MEK and FAK inhibitor could overcome this in-…